The Australian results are still there. Why not get money to run a trial in a similar spectrum of patients? They had some quite remarkable results albeit a small group. Transgene ongoing royalties are key. Milestones are a boost. At the current market cap it's priced for failure. Little Or no value for transgene. I'm gonna hold my remaIning stock for quite some time.
